LifeSci Capital analyst Charles Zhu has maintained their bullish stance on TARA stock, giving a Buy rating on November 10.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Charles Zhu has given his Buy rating due to a combination of factors related to Protara Therapeutics’ promising developments and strategic positioning. The company’s TARA-002 treatment has shown consistent and encouraging results in BCG-naive NMIBC patients, with a high complete response rate observed in recent data updates. This suggests a strong potential for the treatment’s efficacy, which is a positive indicator for the company’s future prospects.
Furthermore, Protara is actively engaging with the FDA to establish a registrational development pathway for BCG-eligible patients, aiming for a control arm with minimal BCG involvement. This strategic move could open up significant market opportunities, especially for patients who are BCG-contraindicated or unable to access BCG. Additionally, Protara’s financial position, with a manageable cash burn and a reasonable cash runway, supports its ability to pursue these developments effectively. These factors collectively underpin Zhu’s optimistic outlook on the stock.
Zhu covers the Healthcare sector, focusing on stocks such as Kura Oncology, Zymeworks, and IDEAYA Biosciences. According to TipRanks, Zhu has an average return of 22.7% and a 65.33% success rate on recommended stocks.
In another report released on November 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $23.00 price target.